Market Research Reports and Industry Reports

Therapeutic Class Report Overview - Hemophilia

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Hemophilia is an inherited (X-linked recessive trait), lifelong bleeding disorder that prevents blood from clotting due to insufficient or lack of adequate amount of clotting factors Factor VIII (FVIII) and Factor IX (proteins in blood that control bleeding). Plasma-derived FVIII and FIX proteins were used in the 70s for treating these disorders but transmission of contaminating viruses reduced its use. In 1999, recombinant FVIIIs and FIX, free of viral, animal, or human proteins became the standard of care (SoC). However, frequent injections used for prophylaxis resulted in development of antibodies (called inhibitors acquired hemophilia or neutralizing abs) to FVIII or FIX. The presence of inhibitors complicated treatment of hemophilia A and B- ~30% in hemophilia A and up to 3 to 5% in hemophilia B pts. The high cost of treatment, frequent dosing, and infusion related adverse events are other concerns.

To address these limitations, companies are developing next generation clotting factors which are more potent Short Acting or Long Acting Recombinant Factors. These potentially could result in fewer injections, reduce the inhibitor level, and improve compliance. Several of these pipeline products are now poised for approval and launch in the next two-three years. At present, Baxter, Bayer/ CSL, Pfizer, Novo Nordisk dominate the current ~$10b hemophilia market. In this report, we have analyzed the clinical efficacy, safety, and commercial prospects of the late-stage products in development and expect the long acting products that have best clinical and safety data to lead by offering patients better Cost per Quality Adjusted Life Year (QALY).
N/A

List Of Tables

N/A

List Of Figures

N/A

Relief Therapeutics Holding AG (RLF) - Financial and Strategic SWOT Analysis Review

Relief Therapeutics Holding AG (Relief Therapeutics) is a drug development company which focuses on the clinical development of peptides and proteins of natural or engineered origin. Its pipeline drug candidates

USD 300View Report

Lumosa Therapeutics Co Ltd (6535) - Financial and Strategic SWOT Analysis Review

Lumosa Therapeutics Co Ltd (Lumosa Therapeutics), formerly SunTen Phytotech Co., Ltd., is a biotechnology company that offers development of new drugs for the treatment of unmet medical needs. The companys

USD 300View Report

Innate Immunotherapeutics Ltd (IIL) - Financial and Strategic SWOT Analysis Review

Innate Immunotherapeutics Ltd (Innate Immunotherapeutics) ,formerly Innate Therapeutics Limited is a biotechnology company that develops therapies. The company designs and develops immunomodulator microparticle technology. It develops therapeutic drugs for the

USD 300View Report

Therapeutic Class Report Overview - Future Of GPR Agonist

Despite about half a dozen distinct targets having been innovated and introduced in the market for the oral treatment of Type 2 diabetes, ~60% of diabetics still exhibit progressive worsening

USD 1000View Report

Therapeutic Class Report Overview : Hepatitis C Virus Infection

The launch of Protease inhibitors (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations

USD 1000View Report

Therapeutic Class Report Overview - Japan Biosimilars

200b worth of biologic products is going off patent by 2015 and this value exceeds ~ 500b if we include products that will see their patent expiries by 2021 in

USD 1000View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 2000
  • Site Licence    $ 4000
  • Enterprisewide Licence    $ 6000
$ 2000

Reports Details

Published Date : Feb 2013
No. of Pages :47
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment